Navigation Links
ATS Medical Announces Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve in Japan
Date:4/16/2009

MINNEAPOLIS, April 16 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the Japanese Ministry of Health, Labor and Welfare has approved commercial distribution of the ATS Open Pivot(R) AP360(TM) Mechanical Heart Valve.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

The ATS AP360 heart valve maximizes hemodynamic performance with a new supra-annular cuff design that facilitates implantation. The original ATS Medical Open Pivot(R) Heart Valve is highly regarded for fundamental design features that promote best-in-class hemodynamic performance, enhanced resistance to blood clot formation and improved patient quality of life through quieter valve operation. In a response to the highly individualized and specific valve selection criteria of cardiac surgeons, particularly with respect to implantability, the ATS AP360 combines proven performance with a cuff design that extends its appeal to a broader spectrum of surgeons.

"Our long time distribution partner, Century Medical, Inc., worked diligently to facilitate this important approval in conjunction with the ATS Quality and Regulatory Organization. The cuff design of the ATS AP360 valve provides significant hemodynamic benefit for patients with a small aortic root and will be ideal for the unique needs of the Japanese market," said Michael Dale, President and CEO of ATS Medical. "The newly approved AP360 will provide even more opportunity to further penetrate the Japanese marketplace."

About ATS Medical

ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive, sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedicAlert Brings History of Saving Lives to Chicago for Inaugural Thrive Allergy & Gluten-free Expo
2. Chicagos Top Minds Join National Business and Health Leaders in Addressing Medical Innovation, Highlighting Policies Needed to Maintain U.S. Competitiveness in Medical Science and Discovery
3. Medical Mutual of Ohio Names Dugan Chief Legal Counsel
4. Frost & Sullivan Recognizes Zecotek Photonics Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology
5. Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics
6. Delta Employees Blanket Salt Lake City Medical Center With Warm Gifts
7. Barry Arbuckle, MemorialCare Medical Center CEO and California Hospital Association Past Chair, Speaks Out on Impact of 3-Year, $32 Million Public-Private Partnership
8. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
9. American Legacy Foundation(R) and Georgetown University Medical Center Create Research Collaboration
10. Former Head of Office of Lilly CME, Steve Davidson, RPh, Named Medical Education Specialist at CME Enterprise
11. The American Federation for Medical Research Unites Top Leaders to Mitigate U.S. Crisis in Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Kansas City, MO (PRWEB) , ... May 25, 2016 , ... ... professional, collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free ... Drug Free Sport”. This conference, to be held July 12 – 13 in Kansas ...
(Date:5/25/2016)... ... May 25, 2016 , ... A new update to ... motion capture, all by utilizing a common Wi-Fi network and a mobile device. When ... from any location with Wi-Fi, and use a mobile device to control the recording. ...
(Date:5/25/2016)... ... , ... According to an article published April 14th on Bioscience ... against common bacteria and protect against surgical site infections. The article explains that this ... even safer and could further reduce the risk of surgery related complications. The ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Horizon Foundation for New ... initiative to improve oral health-related awareness, education, prevention and treatment for young people. ... and promote best practices in 10 New Jersey counties where dental health needs ...
(Date:5/25/2016)... ... , ... The Bank of America Charitable Foundation has awarded a grant to ... pathway to employment and successful careers in healthcare. On Wednesday, May 4th, Rick Bridwell, ... CEO of Medisend, parent organization and home of the General Myers Veterans Program. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
Breaking Medicine Technology: